A Phase 3 interventional study of Pregabalin Dose Level 1 and Pregabalin Dose Level 2 in Partial Onset Seizures, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 72 sites in 23 countries. Open to participants aged 1 Month to 3 Years. Per ClinicalTrials.gov, last updated 2021-01-20.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Epilepsy by Viatris Inc. — none open to participants now, none under way, none of them phase 3. Epilepsy · Viatris Inc..
Among the 19 studies in Epilepsy by Viatris Inc., this one is the 9th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2014, is one of 12 in phase 3, and was the 19th registered.
1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.
Browse Epilepsy studies →None of the 19 studies in Epilepsy by Viatris Inc. is open now. The open studies under Epilepsy, anywhere →
Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.
This study: 1 Month to 3 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 175 is above the median of 50 across 1,239 interventional studies indexed under Epilepsy.
Median enrollment 219 across the 15 interventional studies, 243 across the 4 observational. Of the 19 that completed or were terminated, 18 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Epilepsy by Viatris Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the effectiveness of 2 doses of pregabalin to reduce seizure frequency as an add on therapy in pediatric subjects 1 month to \<4 years of age with refractory partial onset seizures. It is hypothesized that both doses of pregabalin will demonstrate superior efficacy when compared to placebo by reducing the partial onset seizure frequency and that pregabalin will be safe and well tolerated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Pregabalin Dose Level 1
Drug: Pregabalin Dose Level 2
Drug: Placebo
Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 7.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 14.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
Placebo Liquid dosed three times daily beginning at Randomization through Taper Phase
Log Transformed 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase
All partial onset seizures experienced during treatment phase were recorded by central reader during the 48 to 72 hour video-electroencephalogram (EEG). Double Blind 24 hour EEG seizure rate for all partial onset seizures = (\[Number of seizures in double blind 48 to 72 hour EEG assessment\] divided by \[number of hours of video-EEG monitoring\])\*24. The EEG assessment was done at the end of the fixed dose treatment. For log-transformation, the quantity 1 was added to the double blind 24 hour EEG seizure rate for all participants to account for any possible "0" seizure incidence. This resulted in final calculation as: log transformed (double-blind 24-hour EEG seizure rate + 1).
Time frame: Day 1 up to Day 14
Responder Rate: Percentage of Participants With at Least 50 Percent (%) or Greater Reduction From Baseline in 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase
Responder Rate was defined as percentage of participants who had a 50% or greater reduction from baseline in 24-hour seizure rate during the double-blind treatment phase. Double Blind 24 hour EEG seizure rate for all partial onset seizures = (\[Number of seizures in double blind 48 to 72 hour EEG assessment\] divided by \[number of hours of video-EEG monitoring\])\*24. The EEG assessment was done at the end of the fixed dose treatment.
Time frame: Day 1 up to Day 14
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events which occurred between first dose of study drug and up to end of study (up to Day 25) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.
Time frame: Day 1 up to End of study (EOS) (maximum Day 25)
Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events which occurred between first dose of study drug and up to end of study (up to Day 25) that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to drug was assessed by the investigator. AEs included both serious and non-serious adverse events.
Time frame: Day 1 up to EOS (maximum Day 25)
Number of Adverse Events by Severity
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories a) mild: AEs does not interfere with participant's usual function b) moderate: AEs interferes to some extent with participant's usual function c) severe: AEs interferes significantly with participant's usual function.
Time frame: Day 1 up to EOS (maximum Day 25)
Number of Participants With Laboratory Test Abnormalities
Abnormality Criteria: hemoglobin,hematocrit,red blood cells(RBC)count:\<0.8\*lower limit of normal\[LLN\],platelets:\<0.5\*LLN/\>1.75\*upper limit of normal\[ULN\]; leukocytes:\<0.6\*LLN/\>1.5\*ULN; lymphocytes,neutrophils, total protein,albumin, tetraiodothyronine,thyroid stimulating hormone:\<0.8\*LLN/\>1.2\*ULN; basophils,eosinophils,monocytes:\>1.2\*ULN; prothrombin \[PT\],PT international ratio:\>1.1\*ULN; aspartate aminotransferase,alanine aminotransferase,alkaline phosphatase,gamma glutamyl transferase:\>0.3\*ULN; bilirubin:\>1.5\*ULN; blood urea nitrogen,creatinine, cholesterol,triglycerides:\>1.3\*ULN; sodium: \<0.95\*LLN/\>1.05\*ULN; potassium,chloride,calcium,bicarbonate:\<0.9\*LLN/\>1.1\*ULN; glucose fasting:\<0.6\*LLN/\>1.5\*ULN; creatine kinase:\>2\*ULN;urine glucose,ketone,protein:\>=1;urine WBC,RBC:\>= 20/High Power Field\[HPF\]; urine casts,hyaline casts:\>1/Low Power Field; urine bacteria:\>20/HPF.
Time frame: From Baseline up to EOS (maximum Day 25)
Number of Participants With Vital Signs Abnormalities
Criteria for abnormalities in vital signs included: sitting/supine systolic blood pressure (SBP) values: maximum increase and decrease of greater than or equal to (\>=) 30 millimeter of mercury (mmHg) from baseline; sitting/supine diastolic blood pressure (DBP) value: maximum increase and decrease of \>=20 mmHg from baseline.
Time frame: From Baseline (BL) up to EOS (maximum Day 25)
Percentage of Participants With Abnormal Physical Examination Findings at Screening and End of Study
Physical examinations evaluated the following body systems/organs: abdomen; ears; extremities; eyes; general appearance; head; heart; lungs; lymph nodes; mouth; musculoskeletal; nose; skin and throat. Abnormalities in physical examination were based on investigator's discretion.
Time frame: Screening and EOS (maximum Day 25)
Percentage of Participants With Abnormal Neurological Examination Findings at Baseline and End of Study
Neurological examinations included: coordination; cranial nerve function (CNF); gait and station; level of consciousness (LOC); lower and upper extremity sensation; muscle strength; muscle tone; nystagmus; reflexes and speech. Abnormalities in neurological examination were based on investigator's discretion and also, some components of the neurological examination were not done for certain participants due to participant age or significant developmental impairment. Only those categories of neurological examination in which at least 10% of participants had an abnormality in any treatment group at any time point were reported in this outcome measure.
Time frame: Baseline (BL) and EOS (maximum Day 25)
Number of Participants With Electrocardiogram (ECG) Abnormalities
Criteria for abnormalities in ECG findings: 1) Time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS complex): \>=140 milliseconds (msec); 2) The interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval): \>=200 msec; 3) Time from ECG Q wave to the end of the T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula (QTCF interval): absolute value 450 to \<480 msec, 480 to \<500 msec, \>=500 msec; 4) Maximum QT interval: \>=500 msec; 5) Maximum QTCB interval (Bazett's correction): 450 to\< 480 msec, 480 to \<500 msec, \>=500 msec. Only those categories of ECG abnormalities in which participants were found abnormal (maximum QTCB interval 450-\<480 msec), were reported in this outcome measure.
Time frame: From screening up to EOS (maximum Day 25)
| Milestone | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Placebo |
|---|---|---|---|
| Started | 71 | 34 | 70 |
| Completed | 69 | 33 | 67 |
| Not completed | 2 | 1 | 3 |
| Withdrew: Insufficient clinical response | 1 | 0 | 1 |
| Withdrew: No longer willing to participate | 1 | 0 | 1 |
| Withdrew: Medication error | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 |
All partial onset seizures experienced during treatment phase were recorded by central reader during the 48 to 72 hour video-electroencephalogram (EEG). Double Blind 24 hour EEG seizure rate for all partial onset seizures = (\[Number of seizures in double blind 48 to 72 hour EEG assessment\] divided by \[number of hours of video-EEG monitoring\])\*24. The EEG assessment was done at the end of the fixed dose treatment. For log-transformation, the quantity 1 was added to the double blind 24 hour EEG seizure rate for all participants to account for any possible "0" seizure incidence. This resulted in final calculation as: log transformed (double-blind 24-hour EEG seizure rate + 1).
| seizures per 24 hours | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Placebo |
|---|---|---|---|
| Log Transformed 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase | 1.69 ± 0.115 | 1.15 ± 0.163 | 1.58 ± 0.129 |
Responder Rate was defined as percentage of participants who had a 50% or greater reduction from baseline in 24-hour seizure rate during the double-blind treatment phase. Double Blind 24 hour EEG seizure rate for all partial onset seizures = (\[Number of seizures in double blind 48 to 72 hour EEG assessment\] divided by \[number of hours of video-EEG monitoring\])\*24. The EEG assessment was done at the end of the fixed dose treatment.
| percentage of participants | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Placebo |
|---|---|---|---|
| Responder Rate: Percentage of Participants With at Least 50 Percent (%) or Greater Reduction From Baseline in 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase | 30.51 | 53.57 | 41.51 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events which occurred between first dose of study drug and up to end of study (up to Day 25) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.
| Participants | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Placebo |
|---|---|---|---|
| AEs | 32 | 17 | 38 |
| SAEs | 0 | 1 | 4 |
Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were events which occurred between first dose of study drug and up to end of study (up to Day 25) that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to drug was assessed by the investigator. AEs included both serious and non-serious adverse events.
| Participants | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Placebo |
|---|---|---|---|
| AEs | 15 | 8 | 13 |
| SAEs | 0 | 0 | 1 |
An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs were classified according to the severity in 3 categories a) mild: AEs does not interfere with participant's usual function b) moderate: AEs interferes to some extent with participant's usual function c) severe: AEs interferes significantly with participant's usual function.
| events | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Placebo |
|---|---|---|---|
| Mild | 60 | 23 | 67 |
| Moderate | 3 | 13 | 19 |
| Severe | 0 | 0 | 0 |
Abnormality Criteria: hemoglobin,hematocrit,red blood cells(RBC)count:\<0.8\*lower limit of normal\[LLN\],platelets:\<0.5\*LLN/\>1.75\*upper limit of normal\[ULN\]; leukocytes:\<0.6\*LLN/\>1.5\*ULN; lymphocytes,neutrophils, total protein,albumin, tetraiodothyronine,thyroid stimulating hormone:\<0.8\*LLN/\>1.2\*ULN; basophils,eosinophils,monocytes:\>1.2\*ULN; prothrombin \[PT\],PT international ratio:\>1.1\*ULN; aspartate aminotransferase,alanine aminotransferase,alkaline phosphatase,gamma glutamyl transferase:\>0.3\*ULN; bilirubin:\>1.5\*ULN; blood urea nitrogen,creatinine, cholesterol,triglycerides:\>1.3\*ULN; sodium: \<0.95\*LLN/\>1.05\*ULN; potassium,chloride,calcium,bicarbonate:\<0.9\*LLN/\>1.1\*ULN; glucose fasting:\<0.6\*LLN/\>1.5\*ULN; creatine kinase:\>2\*ULN;urine glucose,ketone,protein:\>=1;urine WBC,RBC:\>= 20/High Power Field\[HPF\]; urine casts,hyaline casts:\>1/Low Power Field; urine bacteria:\>20/HPF.
| Participants | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Placebo |
|---|---|---|---|
| Number of Participants With Laboratory Test Abnormalities | 65 | 29 | 61 |
Criteria for abnormalities in vital signs included: sitting/supine systolic blood pressure (SBP) values: maximum increase and decrease of greater than or equal to (\>=) 30 millimeter of mercury (mmHg) from baseline; sitting/supine diastolic blood pressure (DBP) value: maximum increase and decrease of \>=20 mmHg from baseline.
| Participants | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Placebo |
|---|---|---|---|
| Maximum Increase from BL(>=30):sitting/supine SBP | 2 | 0 | 1 |
| Maximum Increase from BL(>=20):sitting/supine DBP | 7 | 1 | 3 |
| Maximum Decrease from BL(>=30):sitting/supine SBP | 1 | 0 | 1 |
| Maximum Decrease from BL(>=20):sitting/supine DBP | 2 | 2 | 1 |
Physical examinations evaluated the following body systems/organs: abdomen; ears; extremities; eyes; general appearance; head; heart; lungs; lymph nodes; mouth; musculoskeletal; nose; skin and throat. Abnormalities in physical examination were based on investigator's discretion.
| percentage of participants | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Placebo |
|---|---|---|---|
| Abdomen: Screening | 4.2 | 5.9 | 2.9 |
| Abdomen: EOS | 4.2 | 5.9 | 1.4 |
| Ears: Screening | 1.4 | 0 | 1.4 |
| Ears: EOS | 1.4 | 0 | 1.4 |
| Extremities: Screening | 14.1 | 26.5 | 15.7 |
| Extremities: EOS | 14.1 | 26.5 | 18.8 |
| Eyes: Screening | 9.9 | 20.6 | 17.1 |
| Eyes: EOS | 9.9 | 20.6 | 18.8 |
| General appearance: Screening | 15.5 | 26.5 | 15.7 |
| General appearance: EOS | 15.5 | 23.5 | 15.9 |
| Head: Screening | 31.0 | 47.1 | 31.4 |
| Head: EOS | 33.8 | 47.1 | 31.9 |
| Heart: Screening | 1.4 | 8.8 | 4.3 |
| Heart: EOS | 1.4 | 5.9 | 4.3 |
| Lungs: Screening | 2.8 | 8.8 | 4.3 |
| Lungs: EOS | 2.8 | 8.8 | 5.8 |
| Lymph nodes: Screening | 0 | 8.8 | 0 |
| Lymph nodes: EOS | 0 | 2.9 | 0 |
| Mouth: Screening | 9.9 | 2.9 | 5.7 |
| Mouth: EOS | 7.1 | 2.9 | 5.8 |
| Musculoskeletal: Screening | 31.0 | 38.2 | 35.7 |
| Musculoskeletal: EOS | 33.8 | 38.2 | 37.7 |
| Nose: Screening | 0 | 2.9 | 0 |
| Nose: EOS | 0 | 0 | 5.8 |
| Skin: Screening | 9.9 | 14.7 | 21.4 |
| Skin: EOS | 8.5 | 14.7 | 21.7 |
| Throat: Screening | 1.4 | 2.9 | 0 |
| Throat: EOS | 0 | 5.9 | 2.9 |
Neurological examinations included: coordination; cranial nerve function (CNF); gait and station; level of consciousness (LOC); lower and upper extremity sensation; muscle strength; muscle tone; nystagmus; reflexes and speech. Abnormalities in neurological examination were based on investigator's discretion and also, some components of the neurological examination were not done for certain participants due to participant age or significant developmental impairment. Only those categories of neurological examination in which at least 10% of participants had an abnormality in any treatment group at any time point were reported in this outcome measure.
| percentage of participants | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Placebo |
|---|---|---|---|
| Coordination- left hand movement (BL) | 1.4 | 11.8 | 8.6 |
| Coordination-left hand movement (EOS) | 1.4 | 8.8 | 10.1 |
| Coordination- right hand movement (EOS) | 2.8 | 5.9 | 10.1 |
| Coordination- romberg test (BL) | 2.8 | 8.8 | 10.0 |
| Coordination- romberg test (EOS) | 2.8 | 5.9 | 11.6 |
| CNF- left eye visual field (BL) | 12.7 | 8.8 | 10.0 |
| CNF- left eye visual field (EOS) | 12.7 | 8.8 | 10.1 |
| CNF: right eye visual field (BL) | 12.7 | 5.9 | 10.0 |
| CNF: right eye visual field (EOS) | 12.7 | 5.9 | 10.1 |
| CNF: left fundoscopic exam (BL) | 12.7 | 26.5 | 12.9 |
| CNF: left fundoscopic exam (EOS) | 12.7 | 23.5 | 14.5 |
| CNF: right fundoscopic exam (BL) | 11.3 | 20.6 | 14.3 |
| CNF: right fundoscopic exam (EOS) | 11.3 | 17.6 | 14.5 |
| CNF: left visual acuity (BL) | 11.3 | 11.8 | 12.9 |
| CNF: left visual acuity (EOS) | 11.3 | 11.8 | 13.0 |
| CNF: right visual acuity (BL) | 11.3 | 11.8 | 11.4 |
| CNF: right visual acuity (EOS) | 11.3 | 11.8 | 11.6 |
| CNF: finger tracking (BL) | 22.5 | 26.5 | 24.3 |
| CNF: finger tracking (EOS) | 21.1 | 23.5 | 26.1 |
| CNF: swallowing (BL) | 14.1 | 14.7 | 14.3 |
| CNF: swallowing (EOS) | 14.1 | 14.7 | 14.5 |
| CNF:Left shoulder,head turn strength (BL) | 11.3 | 2.9 | 7.1 |
| CNF: Left shoulder shrug,head turn strength (EOS) | 11.3 | 2.9 | 10.1 |
| Gait and station - gait (BL) | 52.1 | 50.0 | 45.7 |
| Gait and station - gait (EOS) | 52.1 | 52.9 | 46.4 |
| Level of consciousness (BL) | 5.6 | 20.6 | 5.7 |
| Level of consciousness (EOS) | 7.0 | 20.6 | 2.9 |
| Muscle strength -lower extremities (BL) | 49.3 | 58.8 | 51.4 |
| Muscle strength -lower extremities (EOS) | 49.3 | 58.8 | 53.6 |
| Muscle strength - upper extremities (BL) | 47.9 | 58.8 | 50.0 |
| Muscle strength - upper extremities (EOS) | 49.3 | 58.8 | 52.2 |
| Muscle strength - trunk (BL) | 43.7 | 38.2 | 44.3 |
| Muscle strength - trunk (EOS) | 39.4 | 38.2 | 42.0 |
| Muscle tone - lower extremities (BL) | 64.3 | 73.5 | 63.8 |
| Muscle tone - lower extremities (EOS) | 64.8 | 73.5 | 66.2 |
| Muscle tone - upper extremities (BL) | 64.8 | 73.5 | 63.8 |
| Muscle tone - upper extremities (EOS) | 64.8 | 73.5 | 66.2 |
| Nystagmus - horizontal (BL) | 9.9 | 11.8 | 7.1 |
| Nystagmus - horizontal (EOS) | 8.5 | 11.8 | 5.8 |
| Reflexes - left ankle (BL) | 46.5 | 52.9 | 47.1 |
| Reflexes - left ankle (EOS) | 46.5 | 52.9 | 46.4 |
| Reflexes - right ankle (BL) | 46.5 | 58.8 | 47.1 |
| Reflexes - right ankle (EOS) | 45.1 | 58.8 | 46.4 |
| Reflexes - left babinski (BL) | 42.3 | 47.1 | 47.1 |
| Reflexes - left babinski (EOS) | 40.8 | 47.1 | 47.8 |
| Reflexes - right babinski (BL) | 42.3 | 55.9 | 50.0 |
| Reflexes - right babinski (EOS) | 40.8 | 55.9 | 50.7 |
| Reflexes - left biceps (BL) | 47.9 | 52.9 | 50.0 |
| Reflexes - left biceps (EOS) | 47.9 | 52.9 | 49.3 |
| Reflexes - right biceps (BL) | 46.5 | 58.8 | 52.9 |
| Reflexes - right biceps (EOS) | 46.5 | 58.8 | 52.2 |
| Reflexes - left brachioradialis (BL) | 45.1 | 52.9 | 48.6 |
| Reflexes - left brachioradialis (EOS) | 45.1 | 52.9 | 47.8 |
| Reflexes - right brachioradialis (BL) | 43.7 | 58.8 | 50.0 |
| Reflexes - right brachioradialis (EOS) | 43.7 | 58.8 | 50.7 |
| Reflexes - left knee (BL) | 53.5 | 55.9 | 57.1 |
| Reflexes - left knee (EOS) | 52.1 | 58.8 | 56.5 |
| Reflexes - right knee (BL) | 52.1 | 61.8 | 61.4 |
| Reflexes - right knee (EOS) | 50.7 | 64.7 | 59.4 |
| Reflexes - left triceps (BL) | 46.5 | 52.9 | 45.7 |
| Reflexes - left triceps (EOS) | 46.5 | 52.9 | 44.9 |
| Reflexes - right triceps (BL) | 45.1 | 58.8 | 48.6 |
| Reflexes - right triceps (EOS) | 45.1 | 58.8 | 47.8 |
| Speech - articulation (BL) | 53.5 | 47.1 | 45.7 |
| Speech - articulation (EOS) | 54.9 | 44.1 | 47.8 |
| Speech - language (BL) | 69.0 | 76.5 | 65.7 |
| Speech - language (EOS) | 69.0 | 73.5 | 66.7 |
Criteria for abnormalities in ECG findings: 1) Time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS complex): \>=140 milliseconds (msec); 2) The interval between the start of the P wave and the start of the QRS complex, corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization (PR interval): \>=200 msec; 3) Time from ECG Q wave to the end of the T wave corresponding to electrical systole corrected for heart rate using Fridericia's formula (QTCF interval): absolute value 450 to \<480 msec, 480 to \<500 msec, \>=500 msec; 4) Maximum QT interval: \>=500 msec; 5) Maximum QTCB interval (Bazett's correction): 450 to\< 480 msec, 480 to \<500 msec, \>=500 msec. Only those categories of ECG abnormalities in which participants were found abnormal (maximum QTCB interval 450-\<480 msec), were reported in this outcome measure.
| Participants | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Placebo |
|---|---|---|---|
| Number of Participants With Electrocardiogram (ECG) Abnormalities | 0 | 2 | 0 |
Collected over Day 1 up to End of Study (maximum Day 25). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | 0/71 (0%) | 0/71 (0%) | 32/71 (45.1%) |
| Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | 0/34 (0%) | 1/34 (2.9%) | 16/34 (47.1%) |
| Placebo | 0/70 (0%) | 4/70 (5.7%) | 37/70 (52.9%) |
| Event | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Placebo |
|---|---|---|---|
| PneumoniaInfections and infestations | 0/71 | 1/34 | 0/70 |
| RhinitisInfections and infestations | 0/71 | 0/34 | 1/70 |
| DehydrationMetabolism and nutrition disorders | 0/71 | 0/34 | 1/70 |
| SeizureNervous system disorders | 0/71 | 0/34 | 1/70 |
| ChokingRespiratory, thoracic and mediastinal disorders | 0/71 | 0/34 | 1/70 |
| Event | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Placebo |
|---|---|---|---|
| SomnolenceNervous system disorders | 8/71 | 6/34 | 4/70 |
| Upper respiratory tract infectionInfections and infestations | 5/71 | 4/34 | 8/70 |
| VomitingGastrointestinal disorders | 1/71 | 0/34 | 6/70 |
| PyrexiaGeneral disorders | 4/71 | 2/34 | 4/70 |
| NasopharyngitisInfections and infestations | 1/71 | 2/34 | 3/70 |
| PneumoniaInfections and infestations | 1/71 | 2/34 | 0/70 |
| Viral infectionInfections and infestations | 2/71 | 2/34 | 2/70 |
| SeizureNervous system disorders | 1/71 | 2/34 | 3/70 |
| Decreased appetiteMetabolism and nutrition disorders | 0/71 | 0/34 | 3/70 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/71 | 0/34 | 3/70 |
Safety population included all randomized participants who received at least 1 dose of study drug.
| Age, Continuous(months) | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Placebo | Total |
|---|---|---|---|---|
| Mean | 27.5 ± 12.7 | 28.5 ± 12.5 | 28.8 ± 12.6 | 28.2 ± 12.6 |
| Sex: Female, Male(Participants) | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Placebo | Total |
|---|---|---|---|---|
| Female | 26 | 14 | 32 | 72 |
| Male | 45 | 20 | 38 | 103 |
| Race/Ethnicity, Customized(Participants) | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Placebo | Total |
|---|---|---|---|---|
| Asian | 23 | 10 | 19 | 52 |
| White | 47 | 24 | 49 | 120 |
| Other | 1 | 0 | 2 | 3 |
| Weight(kilogram) | Pregabalin 7 mg/kg/Day or 6 mg/kg/Day | Pregabalin 14 mg/kg/Day or 12 mg/kg/Day | Placebo | Total |
|---|---|---|---|---|
| Mean | 11.7 ± 3.5 | 11.4 ± 3.4 | 11.4 ± 3.1 | 11.5 ± 3.3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2014 to primary completion in Mar 2018, 41 months.
Results were first posted in Oct 2018, 6 months after primary completion.
Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 41 months is below that.
Counting every sponsor, half of 85 studies reached it within 48 months; a quarter within 29 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →